Iovance Biotherapeutics Inc. [NASDAQ: IOVA] gained 3.75% or 0.26 points to close at $7.20 with a heavy trading volume of 3743388 shares. The company report on March 1, 2023 that Iovance Biotherapeutics to Present at Upcoming Conferences.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences:.
H.C. Wainwright Cell Therapy Virtual ConferenceFireside Chat: February 28, 2023, on-demandVirtual.
It opened the trading session at $6.94, the shares rose to $7.37 and dropped to $6.68, the range by which the price of stock traded the whole day. The daily chart for IOVA points out that the company has recorded -34.43% loss over the past six months. However, it is still -32.84% lower than its most recent low trading price.
If we look at the average trading volume of 4.33M shares, IOVA reached to a volume of 3743388 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Iovance Biotherapeutics Inc. [IOVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IOVA shares is $22.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IOVA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Iovance Biotherapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 27, 2023. While these analysts kept the previous recommendation, Goldman raised their target price from $20 to $6. The new note on the price target was released on December 09, 2022, representing the official price target for Iovance Biotherapeutics Inc. stock.
The Average True Range (ATR) for Iovance Biotherapeutics Inc. is set at 0.42 The Price to Book ratio for the last quarter was 2.38, with the Price to Cash per share for the same quarter was set at 2.17.
Trading performance analysis for IOVA stock
Iovance Biotherapeutics Inc. [IOVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.23. With this latest performance, IOVA shares dropped by -9.77% in over the last four-week period, additionally sinking by -34.43% over the last 6 months – not to mention a drop of -44.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IOVA stock in for the last two-week period is set at 49.26, with the RSI for the last a single of trading hit 48.79, and the three-weeks RSI is set at 49.64 for Iovance Biotherapeutics Inc. [IOVA]. The present Moving Average for the last 50 days of trading for this stock 7.00, while it was recorded at 7.18 for the last single week of trading, and 9.17 for the last 200 days.
Iovance Biotherapeutics Inc. [IOVA]: A deeper dive into fundamental analysis
Iovance Biotherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.20.
An analysis of insider ownership at Iovance Biotherapeutics Inc. [IOVA]
There are presently around $1,249 million, or 89.83% of IOVA stock, in the hands of institutional investors. The top three institutional holders of IOVA stocks are: STATE STREET CORP with ownership of 14,715,475, which is approximately 48.16% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 14,463,082 shares of the stock with an approximate value of $104.13 million in IOVA stocks shares; and BLACKROCK INC., currently with $86.95 million in IOVA stock with ownership of nearly 5.325% of the company’s market capitalization.
116 institutional holders increased their position in Iovance Biotherapeutics Inc. [NASDAQ:IOVA] by around 43,254,506 shares. Additionally, 120 investors decreased positions by around 25,789,394 shares, while 36 investors held positions by with 104,493,407 shares. The mentioned changes placed institutional holdings at 173,537,307 shares, according to the latest SEC report filing. IOVA stock had 30 new institutional investments in for a total of 15,622,348 shares, while 50 institutional investors sold positions of 7,843,187 shares during the same period.